Curative Biotechnology (CUBT) Stock Statistics & Valuation Metrics
Total Valuation
Curative Biotechnology has a market cap or net worth of $4.43M. The enterprise value is $10.21T.
- Market Cap
- $4.43M
- Enterprise Value
- $10.21T
Share Statistics
Curative Biotechnology has 6,819,907 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 6,819,907
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Curative Biotechnology’s return on equity (ROE) is 0.37 and return on invested capital (ROIC) is 31.76%.
- Return on Equity (ROE)
- 0.37
- Return on Assets (ROA)
- -1.07
- Return on Invested Capital (ROIC)
- 31.76%
- Return on Capital Employed (ROCE)
- 0.25
- Revenue Per Employee
- 0
- Profits Per Employee
- -565.77K
- Employee Count
- 4
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Curative Biotechnology is -1.60. Curative Biotechnology’s PEG ratio is -0.05.
- PE Ratio
- -1.60
- PS Ratio
- 0.00
- PB Ratio
- -0.84
- Price to FCF
- -4.31
- Price to Operating Cash Flow
- -5.22
- PEG Ratio
- -0.05
Income Statement
In the last 12 months, Curative Biotechnology had revenue of 0 and earned -2.26M in profits. Earnings per share was -0.00.
- Revenue
- 0
- Gross Profit
- -87.84K
- Operating Income
- -1.50M
- Pretax Income
- -2.26M
- Net Income
- -2.26M
- EBITDA
- -1.41M
- Earnings Per Share (EPS)
- -0.00
Cash Flow
In the last 12 months, operating cash flow was -1.03M and capital expenditures 5, giving a free cash flow of -1.03M billion.
- Operating Cash Flow
- -1.03M
- Free Cash Flow
- -1.03M
- Free Cash Flow per Share
- -0.12
Dividends & Yields
Curative Biotechnology pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -23.19%
- Earnings Yield
- -37.89%
Stock Price Statistics
- Beta
- -0.80
- 52-Week Price Change
- -59.50%
- 50-Day Moving Average
- 0.92
- 200-Day Moving Average
- 1.11
- Relative Strength Index (RSI)
- 38.09
- Average Volume (3m)
- 1,036
Financial Position
Curative Biotechnology as a current ratio of 0.01, with Debt / Equity ratio of -22.31%
- Current Ratio
- 0.01
- Quick Ratio
- 0.01
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- -0.93
- Interest Coverage Ratio
- -1.50
Taxes
In the past 12 months, Curative Biotechnology has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Curative Biotechnology EV to EBITDA ratio is -4.93, with an EV/FCF ratio of -5.49.
- EV to Sales
- 0.00
- EV to EBITDA
- -4.93
- EV to Free Cash Flow
- -5.49
- EV to Operating Cash Flow
- -5.49
Balance Sheet
Curative Biotechnology has $145.26K in cash and marketable securities with $1.36M in debt, giving a net cash position of -$1.21M billion.
- Cash & Marketable Securities
- $145.26K
- Total Debt
- $1.36M
- Net Cash
- -$1.21M
- Net Cash Per Share
- -$0.18
- Tangible Book Value Per Share
- -$0.93
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Curative Biotechnology is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- 0
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 30.10%